Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003
- PMID: 15001582
- DOI: 10.1210/jc.2003-031033
Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003
Abstract
Clinical and laboratory investigations starting in 1958 of a group of dwarfed children resembling isolated GH deficiency but who had very high serum levels of GH led to the description of the syndrome of primary GH resistance or insensitivity (Laron syndrome) and subsequently to the discovery of its molecular defects residing in the GH receptor and leading to an inability of IGF-I generation. With the biosynthesis of IGF-I in 1986, therapeutic trials started. Continuously more and more patients are being diagnosed in many parts of the world with a variety of molecular defects. This syndrome proved to be a unique model that enables the study of the consequences of GH receptor defects, the physiopathology of GH-IGF-I disruption, and comparison of the GH-independent IGF-I effects. This review presents the personal experience gained from the study follow-up and treatment of the 60 patients followed up for many years in the Israeli cohort.
Similar articles
-
Prismatic cases: Laron syndrome (primary growth hormone resistance) from patient to laboratory to patient.J Clin Endocrinol Metab. 1995 May;80(5):1526-31. doi: 10.1210/jcem.80.5.7744997. J Clin Endocrinol Metab. 1995. PMID: 7744997 Review.
-
Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.Growth Horm IGF Res. 2016 Jun;28:53-6. doi: 10.1016/j.ghir.2015.08.004. Epub 2015 Aug 18. Growth Horm IGF Res. 2016. PMID: 26307357
-
Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).Pediatr Endocrinol Rev. 2008 Mar;5(3):766-71. Pediatr Endocrinol Rev. 2008. PMID: 18367997 Review.
-
Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.Diabetes Metab. 1996 Jul;22(4):251-6. Diabetes Metab. 1996. PMID: 8767171 Review.
-
Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity.Pediatr Res. 1996 May;39(5):849-55. doi: 10.1203/00006450-199605000-00018. Pediatr Res. 1996. PMID: 8726240
Cited by
-
Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment.Stem Cell Rev Rep. 2023 Feb;19(2):392-405. doi: 10.1007/s12015-022-10457-2. Epub 2022 Oct 21. Stem Cell Rev Rep. 2023. PMID: 36269524 Free PMC article.
-
Genetic Characterization of Short Stature Patients With Overlapping Features of Growth Hormone Insensitivity Syndromes.J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4716-e4733. doi: 10.1210/clinem/dgab437. J Clin Endocrinol Metab. 2021. PMID: 34136918 Free PMC article.
-
Laron Syndrome: A Tale of Two Siblings.J ASEAN Fed Endocr Soc. 2023;38(2):124-127. doi: 10.15605/jafes.038.02.22. Epub 2023 Sep 18. J ASEAN Fed Endocr Soc. 2023. PMID: 38045665 Free PMC article.
-
Growth Hormone insensitivity (Laron syndrome): Report of a new family and review of Brazilian patients.Genet Mol Biol. 2020 Jan 20;42(4):e20180197. doi: 10.1590/1678-4685-GMB-2018-0197. eCollection 2020. Genet Mol Biol. 2020. PMID: 31429861 Free PMC article.
-
Focal Epilepsy in Individuals with Laron Syndrome.Horm Res Paediatr. 2022;95(3):286-290. doi: 10.1159/000524350. Epub 2022 Mar 31. Horm Res Paediatr. 2022. PMID: 35358968 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical